An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Occurence of treatment emergent adverse events during the course of the study

An adverse event (AE) is any untoward medical occurence in a patient or clinical investigation where the study participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame: Baseline (Day 1) to Safety Follow-up (up to Week 60)

Occurence of treatment-emergent serious adverse events (TESAEs)

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death Is life-threatening Requires inpatient hospitalization Results in persistent disability/incapacity Is a congenital anomaly/birth defect Important medical event.

Time frame: Baseline (Day 1) to Safety Follow-up (up to Week 60)

Occurence of treatment-emergent advserse events leading to permanent withdrawal of investigational medicinal product

An adverse event (AE) is any untoward medical occurence in a participant or clinical investigation administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.

Time frame: Baseline (Day 1) to Safety Follow-up (up to Week 60)

Occurence of treatment-emergent infections

Percentage of participants who experienced treatment-emergent infections as adverse events. An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Time frame: Baseline (Day 1) to Safety Follow-up (up to Week 60)